Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Effectiveness of Homologous and Heterologous Covid-19 Boosters against Omicron

25 May 2022

Abstract excerpt

To the Editor: For persons who received a single dose of the Ad26.COV2.S vaccine (Johnson & Johnson-Janssen) against coronavirus disease 2019 (Covid-19), a booster dose of a messenger RNA (mRNA) vaccine at least 2 months after the primary dose is recommended. Recipients of Ad26.COV2.S for both the primary and booster doses may receive a second booster dose of an mRNA Covid-19 vaccine at least 4 months after the...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to COVID-19 Clinical Research Studies
Share to SARS-CoV-2 and COVID-19 Research
Share to SARS-CoV-2 detection and testing

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Source

Identifiers

PMID: 35613039
DOI: 10.1056/nejmc2203165

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 9 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Effectiveness of Homologous and Heterologous Covid-19 Boosters against OmicronPMID 35613039Read ↗

Rapid decline in vaccine-boosted neutralizing antibodies against SARS-CoV-2 Omicron variantSemantic proximity Read ↗

Neutralizing Activities Against the Omicron Variant After a Heterologous Booster in Healthy Adults Receiving Two Doses of CoronaVac VaccinationSemantic proximity Read ↗

Safety, Immunogenicity and Efficacy of the mRNA Vaccine CS-2034 as a Heterologous Booster Versus Homologous Booster with BBIBP-CorV in Adults Aged ≥18 Years: A Randomized, Partial-Blind, Phase 2b TrialSemantic proximity Read ↗

Neutralizing Activities against the Omicron Variant after a Heterologous Booster in Healthy Adults Receiving Two Doses of CoronaVac VaccinationSemantic proximity Read ↗

Antibody Response of Combination of BNT162b2 and CoronaVac Platforms of COVID-19 Vaccines against Omicron VariantSemantic proximity Read ↗

COVID‐19 Vaccine Efficacy and the Evidence on BoostersSemantic proximity Read ↗

Safety and Immunogenicity of Omicron BA.4/BA.5 Bivalent Vaccine Against Covid-19Semantic proximity Read ↗

Rapid Decline in Vaccine-Boosted Neutralizing Antibodies Against SARS-CoV-2 Omicron VariantSemantic proximity Read ↗

Antibody Response of Heterologous vs Homologous mRNA Vaccine Boosters Against the SARS-CoV-2 Omicron Variant: Interim Results from the PRIBIVAC Study, A Randomized Clinical TrialSemantic proximity Read ↗

A Bivalent Omicron-containing Booster Vaccine Against Covid-19Semantic proximity Read ↗

Emerging heterologous mRNA-based booster strategies within the COVID-19 vaccine landscapeSemantic proximity Read ↗

mRNA-Based COVID-19 Vaccine Boosters Induce Neutralizing Immunity Against SARS-CoV-2 Omicron VariantSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.